miRNA-155表达水平对乳腺浸润性导管癌患者预后的影响  

The Effects of the miRNA-155 Expression Level on the Prognosis of Patients with Breast Invasive Ductal Carcinoma

作　　者：张杰[1] 刘悦[1] 高淑萍[1] 朱丽[1] 王贵年 

机构地区：[1]山东万杰医学院医学检验教研室,山东淄博255213 [2]淄博市第一医院检验科,山东淄博255200

出　　处：《医学检验与临床》2014年第5期4-6,共3页Medical Laboratory Science and Clinics

基　　金：山东省科学技术发展计划政策引导类项目（2010YD21021）;淄博市第一医院科研基金资助项目（2010KY）.

摘　　要：目的：探讨miRNA-155基因表达水平与乳腺浸润性导管癌患者预后的关系。方法：应用实时逆转录聚合酶链反应（real time RT-PCR）法检测69例乳腺浸润性导管癌组织和相应正常组织中miRNA-155基因的表达量，分析miRNA-155表达与乳腺浸润性导管癌患者预后的关系。结果：69例乳腺癌组织中，乳腺癌组织miRNA-155的表达量在I、II、III期乳腺浸润性导管癌中表达量递增；多因素Cox回归分析显示，乳腺浸润性导管癌患者的无进展生存时间（PFS）与患者年龄、肿瘤大小、T分期、分化程度无关（均P＞0.05），而与miRNA-155表达水平（P=0.01），淋巴结转移有关（P=0.02）。结论： miRNA-155基因在乳腺浸润性导管癌组织中高表达，具有促癌作用的功能，可作为生物标记评估乳腺浸润性导管癌患者的预后。Objective：To explore the relationship between miRNA-155 gene expression level and the prognosis of patients with breast invasive ductal carcinoma.Methods：Real-time reverse transcriptase polymerase chain reaction is used to detect miRNA-155 expression level both in the breast invasive ductal carcinoma tissue of 69 cases and in the corresponding normal tissues, so as to reveal the relationship between the prognosis of patients with breast invasive ductal carcinoma and miRNA-155 expression levels. Results：Breast tissue expression level of micrornas-155 increases in Phase I, II, III of breast invasive ductal carcinoma; multivariable Cox regression analysis demonstrated that the progression-free survival （PFS） of patients with breast infiltrating ductal carcinoma is unrelated to age, tumor size, T stage or differentiation （P〉 0.05）, but related to the miRNA-155 expression levels （P= 0.01） and lymph node metastasis （P= 0.02）.Conclusions：The expression level of miRNA-155 genes is high in breast invasive ductal carcinoma tissue and can promote cancer. Thus it can be used as biomarkers to assess the prognosis of patients with breast invasive ductal carcinoma.

关 键 词：乳腺癌 miRNA-155 基因表达 预后 miRNA-155 

分 类 号：R737.9[医药卫生—肿瘤]